Trial Profile

A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tocilizumab (Primary)
Indications Pulmonary arterial hypertension
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms TRANSFORM-UK

Most Recent Events

29 Sep 2021 Primary endpoint . (Pulmonary vascular resistance- dynes (cm-5) has not been met according to the results published in the European Respiratory Journal
29 Sep 2021 Results published in the European Respiratory Journal
23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com